OncoMatch/Clinical Trials/NCT06962787
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Is NCT06962787 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Lenvatinib and Pembrolizumab for renal cancer.
Treatment: Lenvatinib · Pembrolizumab · BL-B01D1 · Axitinib — This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 in combination with tyrosine kinase inhibitor (TKI) with or without pembrolizumab (BL-B01D1+TKI±Pembrolizumab) in patients with locally advanced or metastatic renal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose
Cannot have received: mitomycin (mitomycin)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: nitrosourea (nitrosoureas)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: topoisomerase inhibitor
Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin
Cannot have received: immunomodulatory drug
Use of immunomodulatory drugs within 14 days before the first dose of study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06962787 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, mitomycin, nitrosourea disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages